Prosecution Insights
Last updated: October 25, 2026
Application No. 19/057,133

Beauveria Bassiana KNU-101 Strain Having Excellent Insecticidal Effect and Sporulation Potential and Use Thereof

Non-Final OA §103
Filed
Feb 19, 2025
Priority
Nov 16, 2018 — RE 10-2018-0142137 +3 more
Examiner
FAN, LYNN Y
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kyungpook National University Industry-Academic Cooperation Foundation
OA Round
1 (Non-Final)
47%
Grant Probability
Moderate
1-2
OA Rounds
1y 9m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 47% of resolved cases
47%
Career Allowance Rate
232 granted / 490 resolved
-12.7% vs TC avg
Strong +50% interview lift
Without
With
+49.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
74 currently pending
Career history
540
Total Applications
across all art units

Statute-Specific Performance

§101
4.4%
-35.6% vs TC avg
§103
47.2%
+7.2% vs TC avg
§102
8.3%
-31.7% vs TC avg
§112
26.6%
-13.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 490 resolved cases

Office Action

§103
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-4 are currently pending. Claims 1-4 are being examined in this application. Claim Objections Claims 1 and 3 are objected to because of the following informalities: Claim 1, the recitation of “Beauveria bassiana” on line 4 should be italicized. Claim 3, the recitation of “Beauveria bassiana” on line 1 should be italicized. Appropriate correction is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-2 and 4 are rejected under 35 U.S.C. 103 as being unpatentable over Kellar et al (US 2016/0270407 A1; 9/22/2016.). The instant claims recite an insecticidal method comprising a step of treating soil or a plant with a microbial insecticide formulation, wherein said formulation comprises one or more selected from the group consisting of a Beauveria bassiana KNU-101 strain deposited under accession number: KCTC 13660BP, a culture of the strain, a concentrate of the culture, and a dried product of the culture, as an ingredient. Kellar teaches a method for controlling one or more pest with a biopesticide comprising contacting a plant or plant part with one or more of the biopesticides (para 0321), or treating a soil with one or more of the biopesticides (para 0322), wherein said one or more of the biopesticides comprises a Beauveria bassiana strain (para 0083-0084), said biopesticides may be used as a pesticide directly from a culture medium or subject to purification and/or further processing steps (para 0091), said one or more pest comprises thrips (para 0308, 0319), and said biopesticides retain a sufficient effective amount of activity when used (para 0080). The biopesticide may be in the form of granule (para 0067-0068). Kellar does not teach the claimed Beauveria bassiana strain having the claimed accession number (claim 1). However, Kellar does teach said one or more biopesticides comprises a Beauveria bassiana strain, and said one or more biopesticides controls pests including thrips. Hence, Kellar’s strain and the claimed strain exhibit same characteristics – having insecticidal activity against thrips. Therefore, the reference strain would nevertheless have rendered the claimed strain obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, in view of the clear, close relationship between the strains as evidenced by their belonging to the same species and their essential characteristics. Thus, before the effective filing date of the claimed invention, it would have been obvious to one of ordinary skill in the art to substitute Kellar’s strain for other Beauveria bassiana strains such as the claimed strain for the predictable result of controlling one or more pest. Claim 3 is rejected under 35 U.S.C. 103 as being unpatentable over Kellar et al (US 2016/0270407 A1; 9/22/2016.) as applied to claims 1-2 and 4 above, further in view of Nunez-Gaona et al (Braz. Arch. Biol. Technol. 2010;53(4):771-777.). Kellar does not teach the culture medium comprises a mixture of water and bran (claim 3). However, Kellar does teach said one or more biopesticides may be produced in a liquid culture media or a solid culture media fermentation process, the media comprises yeast extract and glycerol (para 0090), and said fermentation process is well known in the art (para 0091). Nunez-Gaona teaches a fermentation process comprising culturing a Beauveria bassiana strain in a medium comprises a mixture of water and bran (p.772 col left – para 3-4). Thus, before the effective filing date of the claimed invention, it would have been obvious to one of ordinary skill in the art to incorporate water and bran, since Kellar discloses that fermentation process of one or more biopesticides including Beauveria bassiana is well known in the art, and Nunez-Gaona discloses that water and bran are routinely incorporated in a Beauveria bassiana culture. Moreover, before the effective filing date of the claimed invention, one of ordinary skill in the art would have been motivated by the cited reference and routine practice to incorporate water and bran, with a reasonable expectation for successfully controlling one or more pest. Conclusion No claims are allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to LYNN Y FAN whose telephone number is (571)270-3541. The examiner can normally be reached on M-F 7am-4pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Curtis Mayes can be reached on (571)272-1234. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Lynn Y Fan/ Primary Examiner, Art Unit 1759
Read full office action

Prosecution Timeline

Feb 19, 2025
Application Filed
Oct 07, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747463
Enhanced Sophorolipid Derivatives
4y 1m to grant Granted Sep 29, 2026
Patent 12734222
METHOD AND MEDICINE FOR TREATING HUNTINGTON'S DISEASE
3y 11m to grant Granted Sep 15, 2026
Patent 12734195
COMPOSITION FOR TREATING INFECTIOUS DISEASES, COMPRISING EXOSOMES DERIVED FROM THROMBIN-TREATED STEM CELLS
3y 4m to grant Granted Sep 15, 2026
Patent 12714130
Single cell protein from thermophilic fungi
3y 2m to grant Granted Aug 25, 2026
Patent 12685289
CONCENTRATED ALGAL EXTRACT
4y 3m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
47%
Grant Probability
97%
With Interview (+49.8%)
3y 5m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 490 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month